Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J. Am. Acad. Dermatol.

Title: Journal of the American Academy of Dermatology

Publisher: Elsevier BV

ISSN (Electronic): 1097-6787

ISSN (Print): 0190-9622

Publication date (Electronic): Jan 2017

Volume: 76

Issue: 1

Affiliations

[1 ] School of Medicine, Yale University, New Haven, Connecticut.

[2 ] Department of Dermatology, Yale University, New Haven, Connecticut; Department of Pediatrics, Yale University, New Haven, Connecticut.

[3 ] Center for Analytical Sciences, Yale University, New Haven, Connecticut.

[4 ] Department of Dermatology, Yale University, New Haven, Connecticut. Electronic address: brett.king@yale.edu.

Article

Publisher Item ID: S0190-9622(16)30763-0

DOI: 10.1016/j.jaad.2016.09.007

PubMed ID: 27816293

SO-VID: ed66683e-29f3-43c7-bccd-4b1a1c33c3b7

History

Keywords: Janus kinase,alopecia areata,tofacitinib

Data availability:

Keywords: Janus kinase, alopecia areata, tofacitinib

Comments

Comment on this article

scite_

Cited by 89

See all cited by